Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Shares Climb 0.2% - Time to Buy?

Key Points

• OACC shares rose 0.2% to $10.67, trading between $10.71 and $10.65, while volume fell 58% below the average daily level.
• Weiss Ratings upgraded the stock from “sell” to “hold,” matching the lone analyst’s Hold rating and MarketBeat’s overall “Hold” consensus.
• Institutional ownership increased, with several funds adding shares, while the company reported quarterly EPS of $0.07. OACC is a SPAC seeking a business combination in the life sciences sector.

Shares of Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) rose 0.2% on Friday. The company traded as high as $10.71 and last traded at $10.67. 22,244 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 53,227 shares. The stock had previously closed at $10.65.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Oaktree Acquisition Corp. III Life Sciences from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, October 2nd. One analyst has rated the stock with a Hold rating. According to data from MarketBeat, the stock presently has an average rating of "Hold".

Oaktree Acquisition Corp. III Life Sciences Stock Performance

The company has a 50 day simple moving average of $10.77 and a 200 day simple moving average of $10.72.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of OACC. Rangeley Capital LLC grew its position in Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company's stock valued at $647,000 after acquiring an additional 21,156 shares during the period. DLD Asset Management LP raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% during the first quarter. DLD Asset Management LP now owns 136,735 shares of the company's stock valued at $1,447,000 after purchasing an additional 1,200 shares during the period. Lineage Point Capital LP acquired a new position in Oaktree Acquisition Corp. III Life Sciences in the 4th quarter worth $2,461,000. Finally, Empyrean Capital Partners LP boosted its position in Oaktree Acquisition Corp. III Life Sciences by 20.0% in the 4th quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company's stock valued at $9,522,000 after buying an additional 150,000 shares during the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences NASDAQ: OACC is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with a company in the life sciences sector.

The company does not operate as a traditional commercial business and does not manufacture or sell products or provide healthcare services. Instead, its activities are focused on evaluating potential merger, acquisition, or other business combination opportunities involving businesses such as biotechnology, pharmaceuticals, medical devices, diagnostics, and related healthcare industries.

Oaktree Acquisition Corp.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.